Stealth BioResubmits Rare Disease Drug Application Amid FDA Challenges
Originally Published 4 months ago — by statnews.com
Stealth BioTherapeutics disclosed an FDA rejection letter to rally support for its experimental drug for Barth syndrome, a rare disease affecting about 150 people in the U.S., amid ongoing struggles to meet regulatory requirements and concerns over the company's future.